Abstract
Objectives: The availability of self-targeting and low immunogenic therapeutic agents is critical to efficient cancer therapy. Therefore, the development of humanized therapeutic antibodies is particularly appealing. Results: A humanized single-chain variable fragment (scFv) antibody that can target human epidermal growth factor receptor-2 (HER2)-overexpressing cancer cells was designed and produced via expression in Pichia pastoris. The expression gave a high yield of 8 mg protein/l (with a purity of 92 %) using shake-flask cultures. Functional studies also revealed that the purified recombinant anti-HER2 scFv exhibited anti-proliferative activity and could bind efficiently to HER2-overexpressing human breast cancer cell line SKBR3. Conclusion: The recombinant scFv offers promising therapeutic and binding efficiencies that are desirable for targeted cancer therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1347-1354 |
| Number of pages | 8 |
| Journal | Biotechnology Letters |
| Volume | 37 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 5 2015 |
Bibliographical note
Publisher Copyright:© 2015, Springer Science+Business Media Dordrecht.
Keywords
- Anti-HER2
- Breast cancer cell line SKBR3
- Cancer therapy
- Heterogeneous expression
- Humanized single-chain variable fragment
- Pichia pastoris
